Inflammation:铁螯合剂和抗癌药物Dp44mT能够减轻过敏性炎症

2018-07-12 AlexYang MedSci原创

之前的研究展示了铁螯合剂和抗癌药物Dp44mT在人类肥大细胞中具有抗炎症作用。然而,Dp44mT在动物模型中的抗炎症作用仍旧不清楚。最近,有研究人员在小鼠中评估了是否Dp44mT能够减轻卵清蛋白(OVA)诱导的过敏性鼻炎症状。研究发现,在注射Dp44mT药物后,AR小鼠中挠鼻子的次数显著减少,组胺和lgE水平在血清中也受到了抑制。另外,OVA可诱导增加血清中白介素(IL)-1β、胸腺基质淋巴细胞生

之前的研究展示了铁螯合剂和抗癌药物Dp44mT在人类肥大细胞中具有抗炎症作用。然而,Dp44mT在动物模型中的抗炎症作用仍旧不清楚。最近,有研究人员在小鼠中评估了是否Dp44mT能够减轻卵清蛋白(OVA)诱导的过敏性鼻炎症状。

研究发现,在注射Dp44mT药物后,AR小鼠中挠鼻子的次数显著减少,组胺和lgE水平在血清中也受到了抑制。另外,OVA可诱导增加血清中白介素(IL)-1β、胸腺基质淋巴细胞生成素(TSLP)和肿瘤坏死因子(TNF)-α水平,但可由Dp44mT的注射而得到显著的抑制。1型T辅助细胞(Th1)因子干扰素-γ水平可由Dp44mT的注射而显著增加,而Th2细胞因子,比如IL-4、IL-5和IL-13的水平则显著的降低。另外,在AR小鼠的鼻内组织中, IL-1β、TSLP、TNF-α和IL-6水平和活性以及半胱天冬酶-1的蛋白水平也可以因Dp44mT的注射而显著降低。有趣的是,Dp44mT在AR小鼠中的注射还能够减少鼻内组织浸润的嗜酸性粒细胞和肥大细胞的数目,具体则是通过抑制巨噬细胞炎症蛋白-2和细胞间黏附分子-1来实现的。

最后,研究人员指出,这些结果表明了Dp44mT在体外和体内中均具有抗炎症的潜力。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-08-05 lxg951
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-07-14 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-07-14 xiaoyeshuang
  7. [GetPortalCommentsPageByObjectIdResponse(id=2057633, encodeId=fbaf205e633dd, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Aug 05 22:38:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046996, encodeId=4d5620469966b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Aug 04 23:38:00 CST 2018, time=2018-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059202, encodeId=9fed205920260, content=<a href='/topic/show?id=5b6d940428a' target=_blank style='color:#2F92EE;'>#过敏性炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94042, encryptionId=5b6d940428a, topicName=过敏性炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu May 30 12:38:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308256, encodeId=69421308256ad, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314778, encodeId=60e41314e786b, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454837, encodeId=9dfa145483ed9, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545558, encodeId=97a815455588b, content=<a href='/topic/show?id=7c4c984645' target=_blank style='color:#2F92EE;'>#inflammation#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9846, encryptionId=7c4c984645, topicName=inflammation)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffd513772211, createdName=ms6980045490879608, createdTime=Sat Jul 14 10:38:00 CST 2018, time=2018-07-14, status=1, ipAttribution=)]

相关资讯

Int Forum Allergy Rhinol:抗组胺剂H1添加到鼻内类固醇中对过敏性鼻炎治疗的影响研究

H1抗组胺剂(AH)和鼻内类固醇(INCS)组合治疗经常用于那些单独使用上述治疗效果不明显的过敏性鼻炎(AR)患者。最近,有研究人员进行了系统性的回顾来确定AH与INCS的组合(AH-INCS)对治疗AR的影响。研究人员利用Medline和Embase数据库进行了文献搜索,并包括了那些随机的、对照试验且研究AH-INCS与INCS单独治疗对治疗AR患者效果比较的文章。研究的初级结果为总鼻症状评分、

AAIR:我国过敏性鼻炎6年增1亿!首部英文版诊疗指南发布

由北京同仁医院耳鼻咽喉头颈外科张罗教授牵头完成的我国首部英文版过敏性鼻炎诊疗指南,近日发表在最新一期《过敏科学、哮喘与免疫学研究》杂志上。

Int Arch Allergy Immunol:过敏性鼻炎患者鼻黏膜细胞和血液中的不同的基因表达模式研究

过敏性鼻炎(AR)基因表达的调查主要依赖于炎症部位的鼻活检样本或者血液样本(系统免疫)来获得用于分析的遗传材料。新的方法避免了侵入性样本搜集,并且为AR中相关的局部免疫机制更深入的了解提供了便利。研究人员在花粉高峰季节搜集了鼻洗液/鼻刷样本和全血样本比较分析了免疫基因的表达情况。研究包括了12名对花粉过敏的成年人(年龄46.3 ± 12.3岁),且患AR时间超过2年。研究发现,在不同的样本类型之间

中国过敏性鼻炎诊治指南(英文版)

过敏性鼻炎是全球性的问题,中国变态反应学会组织相关专家小组共同制定了中国过敏性鼻炎诊治指南。指南主要内容涉及过敏性鼻炎的流行病学,中国主要过敏原介绍,疾病负担,过敏性鼻炎的定义和分类,诊断,治疗,临床结局评估以及患者教育等。

Allergy Asthma Immunol Res:过敏性鼻炎和荨麻疹不充分治疗的经济负担研究

在香港、马来西亚、菲律宾、新加坡、泰国和越南,15.1亿工作人口中大约有3亿-5.3亿患有过敏性鼻炎(AR)和荨麻疹。据估计,大于90%的具有这些过敏性疾病的患者治疗不充分,且因为旷工和生产力降低而对社会经济造成冲击。最近,有研究人员评估了亚种过敏性疾病造成的社会经济负担以及充分治疗下需要的花费。由于区域可利用数据的限制,他们的研究在选择的国家中只关注了AR和荨麻疹。研究人员利用了公开的文献、统计

Allergol Int:抗过敏药物对T细胞调控的鼻高反应性的影响研究

之前,研究人员阐释了T细胞调节的鼻高反应性(NHR)是过敏性鼻炎(AR)的一个代表性病理生理特性。尽管一些抗过敏药物用来治疗AR,而这些药物对T细胞调节的NHR的作用仍旧不清楚。最近,他们调查了地塞米松(Dex)、孟鲁司特(Mik)和氯苯那敏(ChI)对NHR的影响。研究人员对OVA免疫的BALB/c小鼠进行了Dex、Mk或者Chl处理,并且进行了OVA鼻内挑战。研究人员之后评估了NHR、在鼻灌洗